Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

Core Viewpoint - Madrigal Pharmaceuticals, Inc. is set to release its third-quarter 2025 financial results on November 4, 2025, before the U.S. financial markets open [1] Group 1: Financial Results Announcement - The financial results will be followed by a live webcast hosted by Madrigal's management at 8 a.m. Eastern Time [2] - Participants are encouraged to register at least 15 minutes prior to the webcast for a timely connection [2] Group 2: Company Overview - Madrigal Pharmaceuticals focuses on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs [3] - The company's medication, Rezdiffra (resmetirom), is the first and only FDA and European Commission approved treatment for MASH with moderate to advanced fibrosis (F2 to F3) [3] - An ongoing Phase 3 outcomes trial is assessing Rezdiffra for the treatment of compensated MASH cirrhosis (F4c) [3]